INDIANAPOLIS, March 5,
2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:
LLY) today announced that preclinical data for agents targeting
Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented at the
American Association for Cancer Research (AACR) Annual Meeting,
taking place April 5-10 in
San Diego.
The presentations will include new preclinical data for a fully
human monoclonal anti-Nectin-4 antibody conjugated to a novel
topoisomerase I inhibitor and a highly potent and orally
administered inhibitor of KRAS G12D that is selective against
wild-type KRAS. In addition, preclinical data on a potent and
selective BRM (SMARCA2) inhibitor for the treatment of BRG1
(SMARCA4) mutated cancers will be presented in collaboration with
Foghorn Therapeutics. Investigational New Drug (INDs) applications
are planned for all three programs in 2024.
Details on poster presentations are below:
Presentation Title: A next generation treatment for
Nectin-4 positive cancers - Preclinical characterization of
LY4052031, an anti-Nectin-4 antibody, conjugated to a novel
camptothecin payload
Abstract Number: 1872
Session Date &
Time: Monday, April 8, 9:00 a.m. –
12:30 p.m. PT
Session
Title: Antibody-Based Technologies and New
Inhibitors
Presenter: Divya
Sagar
Presentation Title: LY3962673, an oral, highly
potent, mutant-selective, and non-covalent KRAS G12D inhibitor
demonstrates robust anti-tumor activity in KRAS G12D models
Abstract Number: 3316
Session Date &
Time: Monday, April 8, 1:30
p.m. – 5:00 p.m.
PT
Session Title: Novel
Antitumor Agents
3
Presenter: Xueqian
Gong
Presentation Title: Discovery of
selective BRM (SMARCA2) ATPase inhibitors
for the treatment of BRG1 (SMARCA4) mutant
cancers
Abstract Number:
3230
Session Date & Time:
Monday, April 8, 1:30
p.m. – 5:00 p.m.
PT
Session Title: Epigenetic
Targets
Presenter: Janice
Lee
About Lilly
Lilly is a medicine company turning science into healing to make
life better for people around the world. We've been pioneering
life-changing discoveries for nearly 150 years, and today our
medicines help more than 51 million people across the globe.
Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges:
redefining diabetes care; treating obesity and curtailing its most
devastating long-term effects; advancing the fight against
Alzheimer's disease; providing solutions to some of the most
debilitating immune system disorders; and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow
us on Facebook, Instagram and LinkedIn. P-LLY
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about Lilly's oncology pipeline, including therapies under
development, and reflects Lilly's current beliefs and expectations.
However, as with any pharmaceutical product, there are substantial
risks and uncertainties in the process of drug research,
development, and commercialization. Among other things, there can
be no guarantee that studies will be initiated or completed as
planned, that future study results will be consistent with the
results to date, or that any of these therapies will receive
initial regulatory approvals or approvals for additional
indications, as applicable, or be commercially successful. For
further discussion of these and other risks and uncertainties that
could cause actual results to differ from Lilly's expectations, see
Lilly's Form 10-K and Form 10-Q filings with the United States
Securities and Exchange Commission. Except as required by law,
Lilly undertakes no duty to update forward-looking statements to
reflect events after the date of this release.
Refer to:
|
Megan
Talon; megan.talon@lilly.com; 463-209-1470 (Media)
|
|
Joe
Fletcher; jfletcher@lilly.com; 317-296-2884
(Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-announces-details-of-presentations-at-2024-american-association-for-cancer-research-aacr-annual-meeting-302079085.html
SOURCE Eli Lilly and Company